A Second Mechanism for Statin-Associated Muscle Symptoms

Researchers using cryo-electron microscopy have identified a calcium channel disruption mechanism that may explain statin-associated muscle pain in a subset of patients — one that operates independently of CoQ10 depletion.

Approximately 40 million adults in the United States take a statin daily. For the majority, the medication performs as intended: it reduces LDL cholesterol, lowers cardiovascular event risk, and does so with a manageable side effect profile.

For an estimated 4 million of them, however, the medication produces muscle pain, weakness, tenderness, or cramping significant enough to drive discontinuation — even in patients whose cardiologists consider the therapy clinically essential. Statin-associated muscle symptoms, designated SAMS in the clinical literature, have been observed since statins were first prescribed. Their biological explanation has remained incompletely characterized.

The most commonly cited mechanism involves CoQ10 depletion. Statins inhibit HMG-CoA reductase, which suppresses the mevalonate pathway. That pathway produces not only cholesterol but also coenzyme Q10, an electron carrier essential to mitochondrial ATP synthesis. Reduced CoQ10 availability may compromise the energy supply to muscle cells, producing symptoms. The mechanism is real; statins measurably reduce CoQ10 levels. The debate has centered on whether that reduction is sufficient, on its own, to account for the range and severity of symptoms observed clinically. The trial evidence on CoQ10 supplementation for SAMS has been inconsistent.

New research from Columbia University and the University of Rochester may explain part of that inconsistency. A second mechanism exists, and it operates through a fundamentally different pathway.

The Ryanodine Receptor and Calcium Leak

Skeletal muscle contraction is initiated by calcium. When a motor neuron fires, calcium is released from the sarcoplasmic reticulum into the muscle cell cytoplasm, triggering the actin-myosin interaction that produces contraction. Following contraction, the calcium is actively pumped back into storage, allowing the muscle to relax. The channel controlling calcium release from the sarcoplasmic reticulum is ryanodine receptor 1, designated RyR1.

Using cryo-electron microscopy — which resolves biological structures at near-atomic resolution by imaging flash-frozen samples with electron beams — researchers led by Andrew Marks at Columbia University’s Vagelos College of Physicians and Surgeons characterized the interaction between simvastatin and RyR1 directly.

Their finding: simvastatin binds to RyR1 and holds the channel in a partially open state. The consequence is a sustained calcium leak into the muscle cell cytoplasm. When cytoplasmic calcium exceeds the normal physiological threshold, it activates calcium-dependent proteases — specifically calpains — that degrade structural muscle proteins. The downstream result is muscle damage, pain, and weakness. The study was published in the Journal of Clinical Investigation.

Two Mechanisms, Distinct Pathways

The RyR1 calcium leak mechanism and the CoQ10 depletion mechanism describe damage occurring at different biological levels and are not competing explanations.

CoQ10 depletion impairs the mitochondrial electron transport chain, reducing the cell’s capacity to produce ATP. The affected muscle cell has less energy available to sustain contraction, maintain ionic gradients, and pump calcium back into storage. This is an energy supply problem.

The RyR1 calcium leak is a structural problem: the release channel is being held open by a molecule that should not interact with it. A muscle cell with entirely normal mitochondrial function and adequate CoQ10 will still sustain calcium-mediated damage if the RyR1 channel is forced open by statin binding. The two mechanisms are additive in patients where both are active.

This distinction offers a plausible explanation for why the CoQ10 supplementation trials have produced mixed results. If a meaningful fraction of SAMS patients are experiencing symptoms primarily through the RyR1 pathway rather than the CoQ10 pathway, CoQ10 repletion would not be expected to resolve their symptoms, regardless of dose. The heterogeneity in the trial data may reflect genuine mechanistic heterogeneity in the patient population.

Who Faces Elevated Risk

The study found that individuals with existing RyR1 mutations face compounded risk. RyR1 mutations are associated with malignant hyperthermia susceptibility and certain forms of congenital myopathy. In carriers, statin-driven calcium leak through an already-compromised channel may produce more severe or treatment-resistant symptoms.

At the extreme end of the SAMS spectrum lie two rare but serious conditions: rhabdomyolysis, in which muscle tissue breakdown is severe enough to release myoglobin into the bloodstream and precipitate acute kidney injury, and immune-mediated necrotizing myositis, an autoimmune response targeting muscle directly. Both remain uncommon, but both represent the boundary of what sustained, unaddressed muscle damage from statin use can become.

Research Directions

The Columbia group identified two potential approaches to the RyR1 mechanism. The first is pharmacological: designing statin variants that retain HMG-CoA reductase inhibition in hepatic tissue without binding RyR1 in skeletal muscle. This is a drug development question with a long timeline.

The second is more proximal: in statin-intolerant mice, treatment with Rycals — a class of experimental compounds that stabilize RyR1 in a closed state, currently under investigation in rare muscle disease — prevented simvastatin-induced muscle weakness. Rycals are not in general clinical use, but the finding establishes that the calcium leak mechanism is pharmacologically addressable in principle.

“It is unlikely that this explanation applies to everyone who experiences muscular side effects with statins. But even if it explains a small subset, that’s a lot of people we could help if we can resolve the issue.” — Andrew Marks, Columbia University

The Metabolic Support Question

The RyR1 finding does not displace the CoQ10 depletion question; it adds to it. For patients taking statins long-term, mevalonate pathway inhibition measurably reduces CoQ10 synthesis. That consequence is independent of any discussion about RyR1, and the biological rationale for supporting mitochondrial function in long-term statin users remains intact.

The broader principle is that a medication which alters fundamental biosynthetic pathways creates downstream effects throughout the metabolic network. Those effects are quantifiable. Supporting the metabolic systems that statin therapy places under additional demand — mitochondrial energy production, antioxidant enzyme function, muscle cell calcium handling — is a rational complement to lipid-lowering therapy, not a substitute for it. The therapeutic goal is not to avoid statins when they are clinically indicated. It is to ensure that the rest of the physiology is not sustaining unnecessary cost while the medication does its job.

References

Weninger G, Dridi H, Reiken S, et al. Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation. Journal of Clinical Investigation. Published December 15, 2025. DOI: 10.1172/JCI194490.

Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy. Journal of the American College of Cardiology. 2007;49(22):2231–2237.

Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681–1690.

Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: An update. Nutrition. 2010;26(3):250–254.

This article is for informational purposes and does not constitute medical advice. Do not discontinue or modify statin therapy without consulting your physician.

Chris Junge is the founder of Solprana, a supplement and health education company focused on micronutrient restoration and homeostasis. Learn more at solprana.net.